INTRODUCTION {#S1}
============

Spinocerebellar ataxia type 7 (SCA7) is an inherited neurological disorder characterized by cerebellar and retinal degeneration ([@R14]). SCA7 patients develop atrophy of the cerebellar cortex and the brainstem and exhibit extensive loss of cerebellar Purkinje cells ([@R32]; [@R33]). An important feature of SCA7 that allows it to be distinguished from the more than 30 other SCAs, is retinal degeneration. Full-field electroretinograms of SCA7 patients reveal marked dysfunction of cone photoreceptor cells prior to rod photoreceptor abnormalities, establishing SCA7 as a cone-rod dystrophy ([@R55]). As retinal disease progresses, rod photoreceptors become involved, and the visual impairment proceeds to complete blindness. SCA7 is a degenerative disorder with a broad phenotypic spectrum: some SCA7 patients present as children and succumb to disease in less than a decade, whereas other patients remain undiagnosed until middle age and display a slowly progressive course. SCA7 is caused by a CAG/polyglutamine (polyQ) repeat expansion in the gene encoding ataxin-7; the polyQ tract ranges in size from 4 to 35 glutamines in normal subjects but expands to 37 to \>300 glutamines in affected patients ([@R7]; [@R51]). There are nine recognized polyQ repeat diseases, including spinobulbar muscular atrophy (SBMA), Huntington's disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), and six forms of SCA (SCA 1, 2, 3, 6, 7, and 17). Numerous studies have shown that the initiating event in disease pathogenesis is misfolding of the polyQ expansion tract to an altered conformation that is resistant to protein degradation ([@R39]; [@R45]), indicating that SCA7 shares a common pathogenic basis with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis, and tauopathy.

Mitochondria are cellular organelles that are principally responsible for the production of cellular energy in the form of ATP and are the only organelle, other than the nucleus, containing their own DNA. Although the mitochondrial genome encodes fewer than 40 genes, many of these mitochondrial gene products are crucial for proper functioning of the oxidative phosphorylation pathway, where chemical energy is used to power ATP production. Defects in the mtDNA affecting the five multi-protein complexes of the respiratory chain cause a number of different disease syndromes (reviewed in [@R9]). These so-called mitochondrial respiratory chain disorders are quite variable in their phenotypes because of the unique features of mitochondrial genome inheritance and propagation within cells. However, despite the phenotypic variability, one recurrent theme in mitochondrial disease is the propensity for involvement of the CNS and skeletal muscle, tissues that constantly demand high levels of energy for their function. For mitochondrial diseases exhibiting CNS involvement, ataxia due to cerebellar degeneration is a common feature, with one particular syndrome known as NARP (neuropathy, ataxia, and retinitis pigmentosa) repeatedly occurring in patients who display a combination of neuropathy, ataxia, and retinal degeneration.

As mitochondrial dysfunction in mitochondrial genetic disease can often produce ataxia and retinal degeneration, which are defining features of SCA7, and nuclear genetic defects can cause various inherited ataxias with phenotypic overlap with SCA7, we hypothesized a potential role for mitochondrial dysfunction in SCA7. In infantile-onset SCA7, which is typically caused by repeat expansions of more than 180 CAGs, progression is very rapid and patients present with a much broader spectrum of clinical phenotypes than the adult version of the disease, showing hypotonia, muscle wasting, developmental delay, and congestive heart failure ([@R60]. Such infantile-onset SCA7 patients succumb to multi-organ failure ([@R2]; [@R56]; [@R60]). Given the multi-system and severe nature of infantile-onset SCA7, most patients undergo a diagnostic odyssey, with the work-up focused on ruling out lipid storage diseases and mitochondrial disorders ([@R13]; [@R56]). Even the adult form of SCA7 can phenocopy mitochondrial encephalopathies, as these diseases affect similar cell types ([@R13]). Apart from a limited number of case reports, which did reveal abnormal mitochondria in SCA7 patient skeletal muscle and liver ([@R6]; [@R11]; [@R22]; [@R36]), a thorough investigation of mitochondrial involvement in SCA7 has not yet been pursued.

Here we evaluated the potential role of mitochondrial dysfunction in SCA7 through careful study of metabolic and mitochondrial function in SCA7 patients and in SCA7 mice that recapitulate childhood-onset disease ([@R64]). Independent lines of investigation revealed compelling evidence for impaired energy metabolism and abnormal mitochondrial function. Indeed, SCA7 patients displayed impaired brain energy metabolism, and SCA7 mice exhibited decreased oxygen consumption and respiration in metabolic cage studies. In degenerating cerebellar Purkinje cells, we documented abnormal mitochondrial network size, and upon ultrastructural analysis, we observed enlarged individual mitochondria. We created induced pluripotent stem cells (iPSCs) from SCA7 patients and related controls and also developed isogenic cell lines transduced with either normal or polyQ-expanded ataxin-7. Biochemical studies of neural progenitor cells (NPCs) expressing polyQ-expanded ataxin-7 revealed markedly impaired oxidative metabolism and reduced expression of enzymes required for salvage of nicotinamide adenine dinucleotide (NAD^+^). Using recently developed ratiometric NAD^+^ biosensors, we measured NAD^+^ levels in nucleus, cytosol, and mitochondria, and documented significantly decreased NAD^+^ in the nucleus and mitochondria of SCA7 patient NPCs. Metabolomics analysis of SCA7 patients also revealed perturbations in the tryptophan-kynurenine pathway, which provides intermediates for NAD^+^ biosynthesis. Our results suggest that mitochondrial dysfunction, likely due to decreased mitochondrial NAD^+^, is a defining feature of SCA7 disease pathogenesis.

RESULTS {#S2}
=======

SCA7 Shares Clinical Features with Mitochondrial Disorders {#S3}
----------------------------------------------------------

SCA7 is unique among the dominant cerebellar ataxias, as affected patients typically develop retinal degeneration and manifest numerous extra-cerebellar findings, in combination with degeneration of the cerebellum and brainstem ([@R32]; [@R33]). Given the presence of retinal involvement and the breadth of neuropathology in SCA7, the clinical picture of SCA7 is reminiscent of disorders characterized by mitochondrial dysfunction. Indeed, many SCA7 clinical phenotypes are commonly observed in mitochondrial disorders, as 11 of the top 20 disease phenotypes seen in patients with mitochondrial diseases are prominent features of the disease course in most SCA7 patients ([Figure S1A](#SD1){ref-type="supplementary-material"}). To directly determine if SCA7 patients display significant bioenergetics defects, we performed brain 31-phosphorus (^31^P) magnetic resonance spectroscopy (MRS) on a series of 12 SCA7 patients ([Table S1](#SD2){ref-type="supplementary-material"}) and 13 unaffected controls, all previously recruited as part of a large study of inherited SCA ([@R12]). To quantify metabolic energy status, patients and controls carried out a visual task, consisting of a pre-task resting phase, performance of the visual task, and a post-task recovery phase, during which they were subjected to ^31^P MRS of the visual cortex. As expected, controls exhibited a significant increase in the ratio of inorganic phosphate to phosphocreatinine (Pi/P-Cr) during performance of the visual task ([Figure 1A](#F1){ref-type="fig"}), which reflects increased mitochondrial ATP production, the latter being obtained via an elevation in ADP and reflected by a proportional increase in Pi/P-Cr. SCA7 patients, however, did not display a significant alteration in the Pi/P-Cr ratio ([Figure 1A](#F1){ref-type="fig"}), because of impaired mitochondrial oxidative metabolism. To further assess the likelihood that SCA7 is a mitochondrial disorder, we used unbiased hierarchical clustering of SCA7 clinical features with disease phenotypes of known mitochondrial disorders using a bioinformatics algorithm ([http://www.mitodb.com](http://www.mitodb.com/)) ([@R48]). This analysis yielded a "mito-score" for SCA7 of 93 on a scale of 0--100; as a mito-score \>50 indicates significant overlap with mitochondrial disease ([@R48]), this analysis placed SCA7 in association with a number of bona fide mitochondrial disorders, including 3-methylglutaconic aciduria type III (MGCA3) and two forms of optic atrophy ([Figure S1B](#SD1){ref-type="supplementary-material"}). Hence, both ^31^P MRS evaluation of SCA7 patients and consideration of SCA7 clinical symptomatology provide compelling evidence for mitochondrial dysfunction as a central feature of the SCA7 disease process.

SCA7 Mice Exhibit Abnormal Metabolism {#S4}
-------------------------------------

As oxidative metabolism occurs in mitochondria, we initiated our assessment of mitochondrial function in SCA7 by examining metabolic physiology in the SCA7 266Q knockin mouse model, as these SCA7 mice recapitulate a rapidly progressive juvenile-onset form of disease ([@R64]). To quantify metabolic function in living mice, we used the Oxymax/Comprehensive Lab Animal Monitoring (CLAMS) cage system to determine the oxygen consumption rate (OCR) and the respiratory exchange rate (RER) for symptomatic SCA7 266Q knockin mice and wild-type littermate controls. We found that SCA7 mice consumed significantly less oxygen overall with no difference for time of day ([Figures 1B and 1C](#F1){ref-type="fig"}). We also measured RER and observed a significant decrease in RER in SCA7 mice ([Figures 1D and 1E](#F1){ref-type="fig"}), suggesting reduced reliance on glucose oxidation. Taken together, these findings indicate that metabolic function is impaired in SCA7.

Altered Adipose Tissue Stores and Blood Glucose Levels in SCA7 Mice {#S5}
-------------------------------------------------------------------

To further characterize the nature of the abnormal metabolism detected in SCA7 266Q knockin mice, we evaluated their adipose tissue and found that SCA7 fat depots are visibly smaller in comparison with littermate controls ([Figure 2A](#F2){ref-type="fig"}). Analysis of inguinal white adipose tissue (iWAT) revealed that SCA7 mice and littermate controls possess iWAT depots that are comparable as a fraction of total body weight at disease onset, but with disease progression, SCA7 mice display a rapid decrease in iWAT volume in proportion to total body weight, which worsens with disease course ([Figure 2B](#F2){ref-type="fig"}). This dramatic loss of adipose tissue occurs despite the fact that food consumption by SCA7 mice and littermate controls was comparable ([Figure 2C](#F2){ref-type="fig"}) but was accompanied by a significant drop in body weight in SCA7 mice ([Figure S2A](#SD1){ref-type="supplementary-material"}). We also assessed fasting blood glucose levels and found that SCA7 mice and littermate controls display similar blood glucose levels at disease onset, but SCA7 mice exhibit markedly reduced blood glucose levels, once visibly affected with significant neurological abnormalities (Figures [2D](#F2){ref-type="fig"}, [S2B, and S2C](#SD1){ref-type="supplementary-material"}) but prior to late-stage disease ([Figure S2D](#SD1){ref-type="supplementary-material"}). Decreases in adipose tissue content and blood glucose levels imply an abnormal regulation of energy metabolism in symptomatic SCA7 mice. Coupled with the results of metabolic cage experiments, these findings confirm that metabolic respiration is compromised in symptomatic SCA7 mice.

SCA7 Cerebellar Purkinje Cells Have a Fragmented Mitochondrial Network Consisting of Enlarged Individual Mitochondria {#S6}
---------------------------------------------------------------------------------------------------------------------

Purkinje cells in the cerebellum are among the most metabolically active of all neurons ([@R25]), as they process an enormous amount of information from the brainstem and deep cerebellar nuclei to provide the only efferent output leaving the cerebellar cortex for regulation of voluntary movement. In SCA7, Purkinje cell degeneration is prominent; hence, we immunostained cerebellar sections from SCA7 266Q knockin mice and littermate controls with an antibody directed against the outer mitochondrial membrane protein Tom20. We then skeletonized and quantified the Tom20 immunopositive signal to evaluate mitochondrial content and morphology in the soma of Purkinje cells ([Figure 2E](#F2){ref-type="fig"}). By quantifying Tom20 fluorescence as a function of overall cell size, we determined the mitochondrial area and observed a marked reduction in mitochondrial area in SCA7 mice ([Figure 2F](#F2){ref-type="fig"}). When we measured the length of the mitochondrial network in Purkinje cells, we documented a significant reduction in average mitochondrial network length in SCA7 mice in comparison with littermate controls ([Figure 2G](#F2){ref-type="fig"}). A decrease in mitochondrial network length is consistent with a more fragmented mitochondrial network, which has been associated with decreased respiration and defective bioenergetics ([@R27]; [@R58]). To further characterize the morphology of mitochondria at the single organelle level, we pursued ultra-structural analysis on ultrathin sections of cerebellum from SCA7 and control mice. Inspection of the resultant electron micrographs revealed that individual mitochondria in SCA7 mice are obviously larger in both the soma and dendrites of cerebellar Purkinje cells ([Figures 3A and 3B](#F3){ref-type="fig"}). To quantify this apparent difference, we measured the area, perimeter, and feret diameter of individual mitochondria from SCA7 mice and littermate controls and documented that individual mitochondria in SCA7 cerebellar Purkinje cells are much larger in size than mitochondria in control Purkinje cells for all of these readouts ([Figures 3C--3H](#F3){ref-type="fig"}). We also evaluated mitochondrial morphology by assessing circularity and aspect ratio and found that despite the increase in size, mitochondria in SCA7 cerebellar Purkinje cells are similar in shape to mitochondria in control Purkinje cells ([Figures S3A--S3D](#SD1){ref-type="supplementary-material"}), and mitochondrial protein content in SCA7 and control cerebellum is similar ([Figures S3E and S3F](#SD1){ref-type="supplementary-material"}). To assess the status of mitochondria in peripheral tissues, we immunostained skeletal muscle sections from SCA7 266Q knockin mice and littermate controls and noted marked increases in mitochondrial content, size, and network length in SCA7 skeletal muscle, which was accompanied by significant increases in the protein expression levels of Drp1 and Mfn1 ([Figure S4](#SD1){ref-type="supplementary-material"}). We also analyzed liver sections from SCA7 266Q knockin mice and matched controls, and although we noted significantly increased Tom20 immunofluorescence and mitochondrial network length, mitochondrial area and mitochondria-associated protein expression levels were comparable ([Figure S5](#SD1){ref-type="supplementary-material"}).

Development, Comparison, and Validation of Different SCA7 Human Stem Cell Models {#S7}
--------------------------------------------------------------------------------

To determine if the metabolic and mitochondrial defects in SCA7 mice occur in SCA7 patients, we derived iPSCs from SCA7 patients and their related, unaffected relatives ([Figure S6A](#SD1){ref-type="supplementary-material"}) using retroviral transduction ([@R52]). Prior to the use of iPSCs and their derivatives, we confirmed their identity, pluripotency, and ploidy. After generating NPCs, we examined mitochondrial network length via Tom20 immuno-staining and noted a marked reduction in mitochondrial network length in the most severely affected SCA7 patient with a CAG-70 (70Q) repeat expansion mutation but observed only modest decreases in SCA7 patients with CAG-50 (50Q) and CAG-65 (65Q) repeat expansion mutations ([Figure 4A](#F4){ref-type="fig"}). We completed a battery of other assays and did not detect disease-specific phenotypes, despite using multiple clones per genotype. As prior modeling efforts in the CAG-polyQ disease field have shown that greatly expanded CAG repeat alleles are often necessary to elicit disease-specific phenotypes, and stem cell modeling using lines of identical genetic background can greatly reduce spurious effects, we derived a SCA7 stem cell model system that would permit direct comparison of ataxin-7-113Q and normal ataxin-7. To achieve this, we used CRISPR/Cas9 genome editing to first knock out the *ATXN7* gene in patient iPSCs with a guide RNA proximal to the CAG repeats, ensured its efficiency in a surveyor nuclease assay ([Figure S6B](#SD1){ref-type="supplementary-material"}), verified indels in each *ATXN7* allele, and finally confirmed absence of ataxin-7 protein expression ([Figure S6C](#SD1){ref-type="supplementary-material"}). We then reintroduced expression of either normal length ataxin-7-10Q or polyQ-expanded ataxin-7-113Q with eGFP separated by a 2A peptide, or empty vector-eGFP for control purposes, each carried on a lentiviral vector ([Figure 4B](#F4){ref-type="fig"}). The decision to derive vector only, ataxin-7-10Q, and ataxin-7-113Q isogenic iPSC lines reflects the technical challenges encountered with precise genome editing of repetitive sequence contained on a homology stretch that spans the repeat region. Nonetheless, this knockout rescue system permits direct comparison of lines that differ only in the expression of the polyQ expansion tract within the ataxin-7 protein, as we confirmed equivalent levels of expression of ataxin-7-10Q and ataxin-7-113Q protein in the iPSC derivatives and continued to monitor expression levels in all subsequent studies. Indeed, when we compared our SCA7 patient-derived NPCs with our SCA7 knockout rescue NPCs, we found that accumulation of aggregated ataxin-7 protein was similar between SCA7 10Q, 65Q, and 70Q NPCs upon filter trap assay ([Figure 4C](#F4){ref-type="fig"}), while only ataxin-7-113Q NPCs exhibited marked accumulation of aggregated ataxin-7 protein upon filter trap analysis ([Figure 4D](#F4){ref-type="fig"}). The existence of polyQ length-dependent disease phenotypes in this "SCA7 knockout rescue system" was also evident when we studied cell toxicity, as only the SCA7 65Q NPC line displayed significant levels of cell death, with both SCA7 50Q and SCA7 70Q NPCs showing cell death levels comparable with control SCA7 10Q NPCs ([Figure 4E](#F4){ref-type="fig"}); however, we documented markedly increased cell death in ataxin-7-113Q NPCs in comparison with non-transduced NPCs, eGFP-only expressing NPCs, and ataxin-7-10Q NPCs ([Figure 4F](#F4){ref-type="fig"}). These studies thus validate the utility of the SCA7 knockout rescue NPC model as a system for further study of SCA7 metabolic and mitochondrial disease phenotypes.

Polyglutamine-Expanded Ataxin-7 Yields Mitochondrial Abnormalities and Bioenergetics Defects in Transduced NPCs {#S8}
---------------------------------------------------------------------------------------------------------------

To determine if expression of polyQ-expanded ataxin-7 elicits metabolic and mitochondrial phenotypes in human stem cell-derived NPCs, we immunostained knockout rescue NPCs expressing either GFP only, ataxin-7-10Q, or ataxin-7-113Q with an antibody directed against Tom20 ([Figure 5A](#F5){ref-type="fig"}), compared mitochondrial network length, and documented a marked, polyQ length-dependent reduction in mitochondrial network length ([Figure 5B](#F5){ref-type="fig"}). To functionally assess mitochondrial respiration, we performed a bioenergetics profile of non-transduced, GFP-only, ataxin-7-10Q, and ataxin-7-113Q NPCs by performing extracellular flux analysis. We found that ataxin-7-113Q-expressing NPCs display a markedly reduced OCR and greatly increased extracellular acidification rate (ECAR) at baseline to yield a dramatically low OCR/ECAR ratio compared with non-transduced, GFP-only, and ataxin-7-10Q NPCs ([Figure 5C](#F5){ref-type="fig"}). This diminished OCR/ECAR ratio persists in ataxin-7-113Q NPCs upon treatment with the ATP synthase inhibitor oligomycin, the uncoupling agent FCCP, and complex I + III inhibition with combined antimycin and rotenone treatment ([Figure 5C](#F5){ref-type="fig"}).

Biosensor Quantification Reveals Reduced NAD^+^ in Specific Subcellular Compartments in SCA7 Patient NPCs {#S9}
---------------------------------------------------------------------------------------------------------

One possible explanation for impaired oxidative metabolism in SCA7 could be diminished NAD^+^, as NAD^+^ provides substrate for production of NADH, the key electron donor in production of a chemiosmotic gradient that drives oxidative phosphorylation at the inner mitochondrial membrane, and microarray expression analysis of SCA7 266Q knockin mice had previously revealed a significant reduction in the expression of NMNAT1 ([@R15]), which catalyzes synthesis of NAD^+^ from nicotinamide mononucleoside (NMN) in the salvage pathway. The vast majority of NAD^+^ is generated via addition of AMP to NMN in the salvage pathway; however, as NAD^+^ is abundantly required in different subcellular compartments, mammalian cells possess three distinct NMN adenylyltransferases in these different compartments: nuclear NMNAT1, cytosolic NMNAT2, and mitochondrial NMNAT3 ([@R43]). To broadly evaluate NMNAT enzyme expression in SCA7, we performed qRT-PCR analysis of NMNAT1, NMNAT2, and NMNAT3 on RNAs obtained from GFP-only, ataxin-7-10Q, and ataxin-7-113Q NPCs and observed marked reductions in NMNAT1, NMNAT2, and NMNAT3 gene expression in ataxin-7-113Q NPCs, though reductions in NMNAT2 and NMNAT3 were also observed in ataxin-7-10Q NPCs ([Figures 6A--6C](#F6){ref-type="fig"}). We similarly evaluated Sirt3 and Sirt6, two sirtuin family members with links to NAD^+^ metabolism, and documented reductions in Sirt3 expression in ataxin-7-10Q and ataxin-7-113Q NPCs but noted comparable expression levels of Sirt6 ([Figures S6D and S6E](#SD1){ref-type="supplementary-material"}). Immunoblot analysis revealed a reduction in NMNAT1 protein expression in ataxin-7-113Q NPCs but indicated a similar reduction in NMNAT1 protein expression in ataxin-7-10Q NPCs ([Figure 6D](#F6){ref-type="fig"}). Although these findings imply that NAD^+^ production may be impaired in SCA7, they do not provide direct evidence for altered NAD^+^ metabolism in SCA7. Hence, to accurately quantify NAD^+^ levels and do so at the subcellular level, we turned to a recently developed set of NAD^+^ biosensors. In this ratiometric system, NAD^+^ binding yields a loss of fluorescence at an excitation wavelength of 488 nm but does not affect a second excitation peak at 405 nm, permitting normalization ([@R3]). In the presence of reduced NAD^+^, one would expect increases in relative F~488~/F~405~ fluorescence, which we validated in all three NAD^+^ biosensors by measuring a respective increase in the F~488~/F~405~ fluorescence in the nucleus, cytosol, and mitochondria of HeLa cells treated with the NAD^+^ depleting drug FK866 ([Figure S6F](#SD1){ref-type="supplementary-material"}). We then resorted to the use of patient NPC lines, as the knockout rescue system is incompatible with the biosensors because of the presence of GFP. When we compared NAD^+^ levels in control and SCA7 NPCs, we documented a significant decrease in NAD^+^ levels, as reflected by an increase in the 488/405 fluorescence ratio, in the nucleus and mitochondria of SCA7 NPCs ([Figure 6E](#F6){ref-type="fig"}). There was also a strong trend toward reduced cytosolic NAD^+^ levels in SCA7 NPCs, but this difference was not statistically significant (p = 0.09). These findings indicate that metabolic and mitochondrial dysfunction in SCA7 may result from reduced NAD^+^ availability in certain subcellular compartments.

Metabolomics Analysis of SCA7 Patients Reveals Perturbations in the Tryptophan-Kynurenine Pathway {#S10}
-------------------------------------------------------------------------------------------------

Besides the salvage pathway that recycles nicotinamide to produce NAD^+^, there is a *de novo* pathway for NAD^+^ synthesis in which tryptophan is converted to kynurenine and then ultimately to quinolinate, which is a key precursor to NAD^+^ ([Figure S7](#SD1){ref-type="supplementary-material"}). To further assess the status of NAD^+^ production in SCA7, we performed metabolomics analysis on plasma samples from 13 fasted SCA7 patients ([Table S1](#SD2){ref-type="supplementary-material"}) and 35 fasted controls, as part of a larger biomarker study in SCA patients ([@R12]). Using high-resolution mass spectrometry coupled to liquid chromatography (LC-HRMS), we detected and quantified tryptophan and related metabolites from the tryptophan-kynurenine pathway ([Table S2](#SD3){ref-type="supplementary-material"}). Although tryptophan, kynurenine, and the kynurenine/tryptophan ratio were comparable in SCA7 patients and controls ([Figures 7A--7C](#F7){ref-type="fig"}), we observed a trend toward increased levels of 5-hydroxytryptophan in SCA7 patient plasma samples ([Figure 7D](#F7){ref-type="fig"}), indicating reduced flux to the NAD^+^ precursor quinolinate. Furthermore, we found that kynurenic acid and xanthurenic acid were significantly increased in plasma samples of SCA7 patients compared with controls ([Figures 7E--7F](#F7){ref-type="fig"}). Increased production of kynurenic acid and xanthurenic acid in SCA7 patients likely reflects increased activity of kynurenine aminotransferase (KAT), which would hamper the synthesis of the quinolinate precursor and therefore NAD^+^ ([Figure S7](#SD1){ref-type="supplementary-material"}). Interestingly, the same metabolomics analysis was performed on patients with SCA1, SCA2, and SCA3, but such alterations in the tryptophan- kynurenine pathway were not present in these SCA patients (data not shown). These results indicate that tryptophan metabolism and the formation of NAD^+^ intermediates are specifically altered in SCA7 patients and thus corroborate our findings of reduced NAD^+^ levels in human stem cell models of SCA7.

DISCUSSION {#S11}
==========

Mitochondrial dysfunction is emerging as a unifying feature of many neurodegenerative disorders, including AD, PD, and HD ([@R10]; [@R18]; [@R30]). Despite the importance of mitochondrial function for CNS regions that are selectively vulnerable in SCA7, mitochondrial dysfunction in SCA7 has not yet been carefully examined. To determine the role of mitochondrial dysfunction in SCA7 patients, we performed ^31^P MRS of the visual cortex and documented direct evidence for impaired mitochondrial oxidation, on the basis of the inability of SCA7 patients to increase ATP production during completion of a visual task. Changes in the Pi/P-Cr ratio have been linked to altered mitochondrial oxidative metabolism ([@R5]; [@R61]), and previous MRS analysis of patients with HD, a polyQ repeat disease associated with mitochondrial energy deficiency, similarly revealed no change in the Pi/P-Cr ratio during visual stimulation ([@R1]; [@R35]). Importantly, such brain metabolic alterations could be corrected when HD patients were treated with triheptanoin, a drug that directs key substrates to the Krebs cycle ([@R1]). In addition to evaluating mitochondrial dysfunction in SCA7 patients, we pursued an in-depth analysis of the metabolic physiology of SCA7 266Q knockin mice ([@R64]), which recapitulate juvenile-onset disease. Metabolic cages were used to derive accurate measures of OCR and RER and revealed significant deficits in both OCR and RER in SCA7 mice. Similar studies of metabolic physiology have been completed for one other related polyQ disorder, HD, and revealed no differences in basal metabolic rate in one case and an increase in OCR in the other case ([@R21]; [@R59]). Our detection of decreased OCR and RER in SCA7 mice thus provides evidence for physiologically relevant decreases in metabolic processes in a polyQ repeat disease.

After performing *in vivo* metabolic studies, we considered the morphology of the mitochondrial network and of individual mitochondria in cerebellar neurons in SCA7 mice, as bioenergetics defects can reflect abnormalities in mitochondrial dynamics ([@R27]; [@R34]). We observed fragmentation of the mitochondrial network in SCA7 cerebellar Purkinje cells, suggesting that the integrity of the mitochondrial network was not being maintained properly, likely because of defective mitochondrial dynamics. Ultrastructural analysis, however, clearly revealed that individual mitochondria in SCA7 cerebellar Purkinje cells are significantly enlarged not just in Purkinje cell soma but also in dendrites. Although a fragmented mitochondrial network often occurs when individual mitochondria are reduced in size, the relationship between the size of the overall mitochondrial network at micron scale and the size of individual mitochondria at nanoscale is not always absolute ([@R40]). Indeed, yeast mutants, which lack normal mitochondrial fusion or fission and thus possess abnormally small or abnormally large individual mitochondria, can nonetheless maintain a mitochondrial network of normal size ([@R50]). Purkinje cells are exquisitely sensitive to mitochondrial morphology defects, because if mitochondria are too large, they cannot enter the narrow neuronal projections of their elaborate dendritic network ([@R37]). The presence of functioning mitochondria in Purkinje cell dendrites is essential, as Purkinje cells are highly electrically active and thus continually pumping ions across the synapses located in their dendrites, processes that require quick access to large quantities of ATP ([@R25]). Studies of other cerebellar ataxias, such as autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), confirm the importance of mitochondrial size regulation for proper Purkinje cell function, as loss-of-function of sacsin in knockout mice yielded abnormally enlarged mitochondria, which were precluded from entering the narrow neuronal projections of Purkinje cell dendrites, resulting in Purkinje cell degeneration ([@R17]). Similarly in mice, neuron-specific loss of function of Drp1, a key regulator of mitochondrial fission, yields abnormally enlarged mitochondria and severe Purkinje cell degeneration, with a paucity of mitochondria found in Purkinje cell dendrites ([@R37]). Detection of abnormally enlarged individual mitochondria in SCA7 cerebellar Purkinje cells suggests that mitochondrial abnormalities likely play a central role in promoting degeneration of this crucial neuron subtype. Interestingly, despite the presence of a fragmented mitochondrial network in cerebellar neurons in SCA7 mice, we found that the mitochondrial network is actually increased in the skeletal muscle and liver of SCA7 266Q knockin mice, with evidence for increased mitochondrial protein content in skeletal muscle. These findings are consistent with previous studies that reported mitochondrial abnormalities in liver and skeletal muscle biopsies from SCA7 patients ([@R6]; [@R11]; [@R22]; [@R36]).

Although mouse models of SCA7, and of other polyQ repeat diseases, recapitulate many of the defining clinical features of these disorders, there has been great interest in producing neural cells from affected patients by reprogramming terminally differentiated fibroblasts into iPSCs. Here we derived iPSCs from two different SCA7 pedigrees to permit comparison of affected patients with their genetically related unaffected relatives. Despite taking this approach, which should reduce variability because we are comparing individuals with closely related genomes, we did not observe consistent phenotype differences between SCA7 patients and unaffected controls. To create a more powerful stem cell model for SCA7, we used genome editing with CRISPR-Cas9 in order to produce isogenic lines that would differ only in expression of mutant ataxin-7 protein. Although contraction of the CAG repeat expansion to an inframe, normal-sized repeat was not achieved because of the challenges of homologous recombination with targeting fragments containing repetitive sequences, we did produce cell lines with complete knockout of ataxin-7 and transduced one such validated cell line with lentivirus constructs expressing normal ataxin-7, polyQ-expanded ataxin-7, or nothing (i.e., empty vector). We confirmed comparable expression of ataxin-7 by immunoblot analysis of transduced iPSCs and their NPC derivatives and then evaluated mitochondrial network size and metabolic function, after demonstrating that expression of polyQ-expanded ataxin-7 yielded disease-relevant phenotypes in comparison with NPCs expressing normal ataxin-7 or no ataxin-7. We detected fragmentation of the mitochondrial network in the ataxin-7-113Q NPCs and documented marked impairment in mitochondrial bioenergetics by extracellular flux analysis. These findings corroborated observed phenotypes in SCA7 mice, independently validating the existence of mitochondrial dysfunction in SCA7. As this analysis included evaluation of human neural cells lacking ataxin-7, our results indicate that loss of function of ataxin-7 is well tolerated, as non-transduced and GFP-empty transduced ataxin-7 knockout NPCs exhibited mitochondrial networks and bioenergetics comparable with ataxin-7-10Q NPCs. With the potential application of dosage reduction therapies such as antisense oligonucleotides or RNAi for SCA7 and related polyQ ataxias ([@R41], [@R42]; [@R49]), absence of deleterious phenotypes in human ataxin-7 knockout neural derivatives is encouraging, because non-allele-selective interventions are currently envisioned.

So what then is the mechanistic basis for mitochondrial dysfunction in SCA7? The co-existence of bioenergetics defects with aberrant mitochondrial morphology does not allow us to distinguish between defective mitochondrial dynamics or impaired metabolism as the initiating event in the pathogenic cascade, though they are not mutually exclusive. Ataxin-7 is a transcription factor core component of the STAGA co-activator complex ([@R24]; [@R38]), and we, and others, have reported that transcription dysregulation contributes to SCA7 disease pathogenesis ([@R28]; [@R64]). When we considered the results of microarray expression analysis of the SCA7 mouse model used in this study, we noted a marked reduction in the expression of the gene encoding NMNAT1 in SCA7 266Q cerebellum ([@R64]). NMNAT1 is required for generation of NAD^+^ by the recycling of nicotinamide via the salvage pathway, which is the principal pathway by which NAD^+^ levels are maintained. NAD^+^ is emerging as an important regulator of cellular function, and its depletion has been linked to a number of neurodegenerative disorders ([@R31]; [@R47]; [@R57]; [@R62]). Although NMNAT1 is found in the nucleus, and NMNAT2 and NMNAT3 operate respectively in the cytosol and mitochondria, previous work has shown that NAD^+^ levels in one compartment can affect NAD^+^ levels in other compartments ([@R46]), indicating that reduced NAD^+^ production in the nucleus could affect mitochondrial NAD^+^ availability, which in turn would decrease levels of NADH, the electron donor that drives oxidative metabolism at the inner mitochondrial membrane. Furthermore, reduced NAD^+^ in the nucleus alone is sufficient to impair mitochondrial oxidative phosphorylation, as NAD^+^ is the required co-factor for Sirt1, which deacetylates PGC-1α to activate it ([@R44]). PGC-1α co-activates the expression of genes that promote mitochondrial biogenesis or encode many of the enzymes required for both Krebs cycle and oxidative phosphorylation pathway function ([@R26]).

In light of the importance of NAD^+^ production for mitochondrial bioenergetics, we measured the expression of NMNAT1, NMNAT2, and NMNAT3 in our SCA7 knockout rescue stem cell model and noted a marked reduction in NMNAT1 gene expression in ataxin-7-113Q expressing NPCs in comparison with ataxin-7-10Q expressing NPCs. For NMNAT2 and NMNAT3, however, marked reductions were documented in both ataxin-7-113Q and ataxin-7-10Q expressing NPCs, and NMNAT1 immunoblot analysis revealed similar reductions in NMNAT protein expression in ataxin-7-113Q and ataxin-7-10Q expressing NPCs. These findings indicate that altered NAD^+^ production could be occurring in SCA7, but these results were not definitive. To directly measure NAD^+^ levels, and do so in the different subcellular compartments where NMNAT1, NMNAT2, and NMNAT3 function, we used a set of recently developed ratiometric fluorescent biosensors ([@R3]). Using this technique, we determined that NAD^+^ levels are significantly reduced in the nucleus and mitochondria of ataxin-7-113Q-expressing NPCs in comparison with ataxin-7-10Q-expressing NPCs, with a trend toward a significant reduction noted in the cytosol of ataxin-7-113Q NPCs. Direct measurement of NAD^+^ levels in subcellular compartments in SCA7 thus provides evidence for reduced NAD^+^ in mitochondria as a key contributor to the impaired mitochondrial oxidation detected in SCA7 mice and patients. Indeed, previous work indicates that mitochondria NAD^+^ levels are regulated separately from nuclear or cytosolic NAD^+^, because knockdown of NMNAT3 yielded a marked decrease in mitochondrial NAD^+^ without affecting nuclear or cytosolic NAD^+^ levels ([@R3]). In addition to the salvage pathway that recycles nicotinamide to generate NAD^+^, metabolism of tryptophan to kynurenine and then to quinolinate provides a key substrate precursor for *de novo* synthesis of NAD^+^. To determine if altered tryptophan metabolism is also contributing to the shortage of NAD^+^ in SCA7, we performed metabolomics analysis on SCA7 patients and documented marked increases in kynurenic acid and xanthurenic acid, which suggests a metabolic detour to the detriment of quinolinate formation and therefore NAD^+^ synthesis. Hence, we propose that reduced mitochondrial NAD^+^ in SCA7 is contributing to the mitochondrial dysfunction observed in this disorder. As numerous efforts are under way to achieve NAD^+^ repletion as a treatment for age-related diseases, including neurodegenerative disorders ([@R19]), our results may have therapeutic implications for SCA7 and also for other related neurodegenerative diseases, in which mitochondrial involvement is likely.

STAR★METHODS {#S12}
============

CONTACT FOR REAGENT AND RESOURCE SHARING {#S13}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Albert La Spada (<al.laspada@duke.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S14}
--------------------------------------

### Cell Lines {#S15}

Fibroblasts were generated from dermal biopsies from SCA7 patients and controls, upon informed consent and in compliance with UCSD and Duke IRB protocols. Age, genotype, and sex of each resultant cell line is defined in [Figure S6A](#SD1){ref-type="supplementary-material"}. Low passage fibroblast cultures were treated with the retroviral reprogramming factors Oct4, Sox2, Klf4, and c-Myc, as described previously ([@R53]). After 15-20 days, individual colonies with stem cell morphology were isolated and transferred to feeder free conditions and thereafter maintained on Matrigel (BD Bioscience) coated plates and grown in mTesr1 media (StemCell Technologies) as clonal lines. Thereafter, cells were passaged manually by cutting colonies with a needle and scraping resulting sections off the plate before transferring to a new dish. All iPSCs were maintained in 4% O~2~/5% CO~2~ at 37°C with daily medium changes. Characterization of resulting iPSC lines and NPC differentiation is described below in Method Details.

### Animals {#S16}

All animal experimentation adhered to NIH guidelines and was approved by and performed in accordance with the University of California, San Diego and Duke University Institutional Animal Care and Use Committees. The development of the SCA7 266Q mice has been previously described (([@R64]). SCA7 266Q animals were maintained on the FVB/NJ background and then backcrossed onto the C57BL/6J strain background. Mice were housed in a temperature- and humidity-controlled environment on a 12-hour light/dark cycle with food and water *ad libitum*. Hemizygous and age-matched wild-type littermates were used for all experiments. Ages and sample sizes are indicated in each associated figure legend. Because of challenges with breeding the SCA7 266Q line, only female mice were used in metabolic experimentation and quantification of fat percentage, food intake, and glucose levels. For microscopy experimentation, females and males were used in equal numbers, or as close to equal numbers as possible, and studies were performed by an examiner blinded to the treatment.

### Human subject studies {#S17}

The patient study (NCT 01470729) was sponsored by the Assistance-Publique des Hôpitaux de Paris and approved by the local ethical committee (AOM10094, CPP Ile de France VI, Ref: 105-10). All participants were over 18 years and signed a written informed consent before they participated in the study. The patient group consisted of 6 men and 6 women aged from 22 to 76 years old. Sample sizes are indicated in each associated figure legend.

METHOD DETAILS {#S18}
--------------

### 31-Phosphorus functional magnetic resonance spectroscopy (^31^P-MRS) {#S19}

^31^P-MRS data were acquired on a 3-Tesla whole-body Siemens Magnetom Trio scanner, as previously described ([@R1]; [@R35]). A6-cm^31^P transmit/receive surface coil (RAPID Biomedical GmbH; Rimpar, Germany) was used to collect free induction decays at the three phases from the visual cortex of 12 SCA7 patients and 13 healthy controls. The ratio of inorganic phosphate (Pi) to PCr (Pi/P-Cr ratio) was calculated to evaluate the brain response to cortical activation.

### Metabolomics analysis on plasma samples {#S20}

Details about reagents, sample preparations, experimental settings and data-processing were as published previously ([@R12]). Metabolomics features related to tryptophan metabolism were identified based on their mass over charge ratio (*m/z*), their MS/MS spectra, and their retention times using an *in-house* database generated from available commercial standards ([@R12]).

#### MitoDB analysis {#S21}

SCA7 was queried against the MitoDB database \< [http://www.mitodb.com](http://www.mitodb.com/)\> with incidence of 100% ataxia, 83% visual acuity, 30% visual impairment, 69% optic atrophy, 43% pigmentary retinopathy, 70% ophthalmoplegia, 50% pyramidal signs, 50% extrapyramidal symptoms, 50% spasticity, and 25% hearing loss.

#### Mouse phenotyping studies {#S22}

For neurological dysfunction studies, mice were visually inspected by a blinded examiner for obvious neurological signs and examined using a composite neurological evaluation tool (ledge test, clasping, kyphosis and gait were scored on a scale of 0 (normal) to 3 (severely impaired)), as described previously ([@R20]). Females and males were used in equal numbers, or as close to equal numbers as possible, and studies were performed by a blinded examiner. For survival studies, animals were monitored daily and pronounced dead when respiration or heartbeat was no longer present.

#### Fluorescence microscopy {#S23}

Ten-week-old mice were deeply anesthetized with isoflurane and perfused with 4% PFA. Brains were dissected, immersed in 30% sucrose, and cut on a vibrating microtome into 30 um sagittal sections. These free-floating sections were incubated in blocking solution containing 10% goat serum, 1% BSA, and 0.3% Triton X-100 for 1 hr at RT. The quadriceps muscles and livers were removed and snap-frozen in an isopentane bath cooled by liquid nitrogen and stored at −80°C until use. 5-μm cross sections were cut using a cryostat at −20°C, collected on glass slides, and dried at RT for 10 min. The sections were fixed in 1.5% PFA followed by incubation in 0.05% Triton X and subsequently blocked via incubation in 5% BSA in PBS for 1 hr at RT. Primary antibodies, anti-Calbindin antibody (Sigma-Aldrich, C9848) and anti-Tom20 (Santa Cruz, sc11415), were diluted 1:500 in blocking solution and sections were incubated overnight at 4°C. After 2 washes with PBS, sections were incubated with anti-mouse superclonal AlexaFluor 488 and anti-rabbit AlexaFluor 555 (Fisher) at 1:500 and 1:250 dilutions, respectively, for 1 hr at RT. Sections were then washed one time in PBS, incubated in PBS supplemented with 1:5000 Hoechst 33342 for 10 min at RT, and washed again before mounting on glass slides with Prolong Gold anti-fade reagent (Life Technologies). Images were taken on a fluorescence microscope (Z1 Axio Observer Apotome or LSM 880 inverted confocal microscope with AiryScan, Zeiss). Equivalent numbers of fields were captured for each condition. Each Purkinje cell soma was manually encircled based on Calbindin staining and morphometry parameters were quantified by an ImageJ plugin, as described previously ([@R8]). Mitochondrial area was calculated as a percentage of the soma area. Average mitochondrial length was quantified in microns.

#### Electron microscopy and mitochondrial ultrastructure {#S24}

Eight and half-week-old mice were deeply anesthetized with isoflurane and perfused with a fixative solution made of 2% PFA and 2.5% glutaraldehyde in PBS. Brains were dissected and placed in fixative solution overnight at 4°C. The brains were cut on a vibrating microtome into 50 um sagittal sections. Ultrathin sections were prepared from equivalent regions within the cerebellum and imaged at 4000x on a Carl Zeiss Libra 120kV PLUS Energy Filtered Transmission Electron Microscope at the Salk Institute Biophotonics Core. Individual mitochondria were traced in ImageJ and measured for area, perimeter, feret diameter (caliper length), circularity (4πA/p^2^), and aspect ratio (major axis/minor axis).

#### Metabolic studies Indirect calorimetry in metabolic cages {#S25}

Female 8.5-week-old mice were housed in the Oxymax/CLAMS metabolic cage system from Columbus Instruments for 4 days with *ad libitum* access to food and water on a 12 hr light/dark cycle. VO2 and RER were measured by the Oxymax system after a 24 hr acclimation period.

#### Glucose measurement and iWAT dissection {#S26}

Glucose was measured using the NovaMAX glucometer system via tail venipuncture after 6 hr of fasting. The whole mouse was weighed just prior to anesthetization, then sacrified and the inguinal white adipose tissue from the right side of each mouse was surgically excised and weighed as described previously ([@R29]). Variance in sample size between groups at different time points occurred due to increased sampling rate of both genotypes at later time points for other lines of experimentation.

#### RT-PCR analysis {#S27}

RNA was extracted from cells using TRIzol reagent (Thermo Fisher), and DNase-treated with TURBO DNA-free kit (ThermoFisher) according to manufacturer's instructions. One microgram (ug) of RNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies) according to manufacturer's instructions. cDNA was then amplified using a Taqman probe against NMNAT1.

#### Protein isolation and immunoblotting analysis {#S28}

Cells were harvested in RIPA buffer (50 mM Tris, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 150 mM NaCl) supplemented with 1% protease inhibitor cocktail (Roche) and homogenized by passing 5 times through a 23-gauge needle. Lysate was then centrifuged at 10000 x *g* for 10 min at 4°C. Supernatant was quantified via BCA assay (Pierce; ThermoFisher). Fifteen micrograms of protein were separated on 4%--12% Bis-Tris gels (Life Technologies), transferred to PVDF membranes (Millipore), and blocked with 3% Bovine Serum Albumin (Sigma-Aldrich) for at least 1 hr at RT. Membranes were then probed with rabbit anti-ATXN7 (Thermo, PA1-749) 1:1000, mouse anti-polyQ 1C2 (Millipore MAB1574), rabbit anti-TOMM20 (Novus NBP1-81556) 1:1000, mouse anti-MFN1 (Abcam ab57602) 1:1000, mouse anti-DRP1 (Abcam ab56788) 1:1000 or mouse anti-beta actin (Abcam, ab8226) 1:10000 in 3% BSA in PBS overnight at 4°C. After 3 washes with 1x phosphate buffered saline supplemented with 0.1% Tween20 (PBS-T), membranes were incubated with HRP secondary antibodies (1:10000 Santa Cruz sc-2005 \[anti-mouse\], sc-2004 \[anti-rabbit\]) in PBS-T for 1 hr at RT. After treatment with ECL detection reagent (Denville), the membranes were visualized by autoradiography. For the filter trap assay, 30 mg of protein was loaded in a PR-600 24 slot blot filtration manifold unit (Hoefer, Fisher Scientific) with a cellulose acetate membrane. Vacuum was applied until lysate had run through, membrane was blocked in 5% nonfat dried milk in PBS for 1 hr at RT, and then incubated in mouse anti-polyQ 1C2 (Millipore MAB1574) 1:1000 overnight at 4°C. Membranes were then incubated in anti-mouse secondary antibody (1:5000; Santa Cruz sc-2005) for 1 hr at RT, and visualized as above.

#### Immunohistochemistry {#S29}

Cells were grown in coated 96-well plates or chamber slides, fixed in 4% paraformaldehyde for 10 min, and permeabilized in 0.3% Triton X-100 in PBS for 10 min. Cells were then blocked with 5% BSA for at least 1 hr before incubation with chicken anti-GFP (Abcam, ab13970) 1:2000, rabbit anti-Tom20 (Santa Cruz, SC11415) 1:500, mouse anti-SSEA4 (Cell Signaling CS 4755) 1:500, mouse anti Tra-1-60 (Cell Signaling CS 4746) 1:500, mouse anti Tra-1-81 (Cell Signaling CS 4745) 1:500, rabbit anti-Pax6 (Covance, PRB-278P) 1:500, or mouse anti-Nestin (Abcam, ab6142) 1:1000 overnight at 4°C. Cells were washed 3 times with PBS, then incubated with AlexaFluor 488, AlexaFluor 555, and/or AlexaFluor 647 (Fisher) at 1:500 dilutions for 1 hr at RT. To stain nuclei, cells were incubated with 1:10000 Hoechst 33342 (Life Technologies). Cells were preserved in Prolong Gold anti-fade reagent (Life Technologies) and imaged on a fluorescence microscope (Z1 Axio Observer Apotome, Zeiss). Mitochondrial length was quantified using an ImageJ mitochondrial morphometry plugin as described previously ([@R8]).

#### Stem cell modeling iPSC characterization {#S30}

Standard G-banding chromosome analysis of iPSC clones was performed by Molecular Diagnostic Services (San Diego, CA). Digital karyotyping was performed by hybridization to the Illumina Infinium HumanCoreExomeBeadChip (module version 1.9.4) following the manufacturer's instructions. Analysis was performed using the cnvPartition program (Illumina) and gada R package \< <http://www.creal.cat/jrgonzalez/software.htm#ancla-MAD>\>, in addition to manual analysis.

#### Guide RNA design and efficacy {#S31}

The target sequence for the guide RNA was designed and selected using the E-CRISP design site based on proximity to CAG repeat region and limited off-target effects (<http://www.e-crisp.org/E-CRISP/>). The target sequence (CGGGCCGCGGATGACGTCAGG) was incorporated into a synthesized GeneArt DNA String (Life Technologies), as described ([@R63]). This fragment and the pUC57 expression vector were simultaneously digested with EcoR1 and Pst1 restriction enzymes, ligated together, and transformed into DH5α bacteria. Surveyor nuclease assay was performed by PCR amplifying the region surrounding the putative cut site with the following primers: SCA73.1F 5′-GAGCGGAAAGAATGTCGGAGCG-3′ and SCA73.327R 5′-CAGGAACTTTGGAAGCCTCAACCC-3′. The PCR product was hybridized and treated with Surveyor Nuclease S and Surveyor Enhancer S according to manufacturer instructions (Transgenomic, Inc.).

#### CRISPR/Cas9 gene editing and screening {#S32}

One clonal line of patient iPSCs was treated overnight with 5 uM ROCK inhibitor (Ri) (Tocris), then dissociated to single cells with Accutase (StemPro, ThermoFisher), and passed through a 40 μm nylon mesh (BD Biosciences) to ensure single cells prior to transfection. Using Human Stem Cell Nucleofector Kit 2 and Amaxa program B16 (Lonza), 2 × 10^6^ cells were nucleofected with 9 mg of the CMV::Cas9-2A-EGFP vector or CMV::Cas9D10A-2A-EGFP (gifts from Kiran Musunuru; Addgene, \#44719 and \#44720) and 3 μg of the U6::gRNA vector. Transfected cells were plated in mTeSR supplemented with 5 μM Ri for 48 hr before FACS. GFP-expressing cells were selected using the BD influx at the UCSD Human Embryonic Stem Cell Core Facility. Isolated colonies were selected, expanded, and genomic DNA was extracted (DNeasy kit, QIAGEN) for PCR and sequencing analysis. All clones were initially screened by PCR using the PCRx enhancer system (Invitrogen, Life Technologies). Several clonal lines were further investigated by TOPOcloning (ThermoFisher) the PCR product, selecting 10 resulting bacterial clones, isolating DNA (QIAprep kit, QIAGEN), and sequencing (Eton Bioscience; San Diego, CA). One resulting clonal line was selected for further studies.

#### NPC differentiation {#S33}

NPCs were generated from iPSCs described above with STEMdiff Neural Induction Medium (NIM) (StemCell Technologies) according to manufacturer's 'monolayer culture protocol' instructions and maintained in Neural Progenitor Medium (NPM) for 5-15 passages in 4% O~2~/5% CO~2~ at 37°C with medium changes every 2-3 days per manufacturer's instructions.

#### Lentivirus generation and treatment {#S34}

EGFP-2A-puroR-2A, EGFP-2A-puroR-2A-Atxn7cDNA (10 CAG), and EGFP-2A-puroR-2A-Atxn7cDNA (113 CAG) cassettes were cloned into pSico lentiviral constructs. Lentiviral particles were produced using standard techniques, NPCs were transduced with lentivirus, and experiments were all performed after 48 to 72 hr.

#### Extracellular flux analysis {#S35}

For Seahorse analysis (XF96, Agilent Technologies), NPCs were seeded at a density of 3×10^å^4/well in XF96 plates. After 48 hr, cells were tested for both OCR and ECAR (extracellular acidification rate) following manufacturer's instructions with the injection of Seahorse XF Cell Mito Stress Test Kit (Agilent Technologies).

#### NAD^+^ measurement {#S36}

HeLa cells were plated at a concentration of 1.6 × 10^4^ cells/well in a 96 well plate. Each well was transfected with lipofectamine and 0.2 ug plasmid for either cytoplasmic, nuclear, or mitochondrial NAD sensor (or cpV control) ([@R3]), treated with 10 nM FK866 for 11 -- 18 hr, and analysis run 48-72 hr post-transfection. Each NPC line was plated at 1-2 × 10^5^ cells/well in a 96 well plate. Each well was treated with 0.1 uL lentivirus prepared with either cytoplasmic, nuclear, or mitochondrial NAD sensor, or cpV control lentiviral vectors and analysis run 72 hr post-transduction. NPC experiments were performed 3 times as technical replicates, with 2 clones each from 2 controls or 2 SCA7 patients.

#### Flow cytometry analysis {#S37}

Cells were prepared for analysis by removing media and dissociating with 25 uL of accutase per well (incubated at 37°C for \~10 min), followed by dilution and trituration with 100 uL of FACS buffer (PBS with 2% FBS, 2 mM EDTA, 25 mM HEPES) to single cells (125 uL total volume in each well). Analysis was performed on a BD Canto-flow cytometer with the following parameters: FSC voltage − 220, SSC voltage − 300, FITC voltage − 320, AmCyan voltage − 300. Events were recorded for 90 uL total per well. Events were gated for live cells by FSC-A x SSC-A, single cells by FSC-W x FSC-A, and then for cells that expressed the sensor by 405 nm excitation (AmCyan) x 488 nm excitation (FITC). The final gate was determined based upon a non-transfected control. Post-capture final analysis was performed using FlowJo based on the gates above. Statistics were determined using the "Derive Parameters" function for the AmCyan/FITC gate, which gave the per-cell 488/405 fluorescence ratio. The median for each well was calculated and then averaged with other wells from the same treatment/cell line.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S38}
---------------------------------------

All sample sizes, details, and statistical tests can be found in accompanying figure legends. Statistical analysis was done using Microsoft Excel, Prism 6.0 (GraphPad), SigmaPlot (Systat Software), Origin (Origin Labs), and galaxy workflow4metabolomics ([@R16]). Statistical significance was defined at p \< 0.05. For one-way and two-way analysis of variance (ANOVA), if statistical significance (p \< 0.05) was achieved, then we performed post hoc analysis corresponding to the experiment, as specified, to account for multiple comparisons. All t tests were two-tailed Student's t tests, and level of significance (alpha) was always set to 0.05. Statistical analysis of metabolomics data relied upon non-parametric Wilcoxon tests, with the level of significance (alpha) also set to 0.05.
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![Both SCA7 Patients and SCA7 Mice Exhibit Impaired Metabolic Respiration\
(A) Results of^31^P functional magnetic resonance spectroscopy on 12 spinocerebellar ataxia 7 (SCA7) patients and 13 normal controls during performance of a visual task. A significant increase in the ratio of inorganic phosphate to phosphocreatinine (Pi/P-Cr) during performance of the visual task in comparison with recovery occurred for normal controls, but no change in Pi/P-Cr was noted for SCA7 patients. \*p \< 0.05 (two-tailed t test). Error bars represent within-subject differences of corrected SEM on normalized data.\
(B) Metabolic cage measurement of the oxygen consumption rate (VO~2~; mL/kg/h) quantified by area under the curve (AUC) over the course of 72 h. White panels indicate light (day) periods, and gray panels indicate dark (night) periods; 8.5-week-old wild-type (WT) control and SCA7 mice; n = 5 mice/genotype; \*\*p \< 0.01 (two-tailed t test). Error bars indicate SEM.\
(C) Quantification of average measurements of oxygen consumption rate (OCR) during light and dark intervals from (B). \*\*p \< 0.01 (two-tailed t test). Error bars indicate SEM.\
(D) Respiratory exchange ratio (RER) (CO~2~ emission/O~2~ consumption), quantified by area under the curve (AUC) over the course of 72 h. White panels indicate light (day) periods, and gray panels indicate dark (night) periods; 8.5-week-old WT and SCA7 mice; n = 5 mice/genotype; \*p \< 0.05 (two-tailed t test). Error bars indicate SEM.\
(E) Quantification of average measurements of RER during light and dark intervals from (D). \*p \< 0.05 and \*\*p \< 0.01 (two-tailed t test). Error bars indicate SEM.](nihms-1519906-f0002){#F1}

![SCA7 Mice Exhibit Reduced Fat Stores, Decreased Blood Glucose Levels, and Altered Mitochondrial Network Integrity\
(A) Representative images of inguinal white adipose tissue (iWAT) from two SCA7 and two WT mice at 8.5 weeks of age.\
(B) iWAT was dissected and weighed as a proportion of body weight at indicated ages. WT and SCA7 mice; n = 3--6 mice/genotype at 30, 40, and 50 days of age; n = 20 mice/genotype at 60 days of age; \*\*p \< 0.01 and \*\*\*\*p \< 0.0001 (two-tailed t test).\
(C) Cumulative food intake over time course for WT and SCA7 mice; n = 3 mice/genotype.\
(D) Blood glucose levels after 6 h of fasting at indicated ages. WT and SCA7 mice; n = 3--6 mice/genotype at 30, 40, and 50 days of age; n = 20 mice/genotype at 60 days of age; \*\*p \< 0.01 (two-tailed t test).\
(E) Representative images of skeletonized Tom20 signal within a Purkinje cell body to exhibit extremes of length measurement. The average length of the depicted WT mitochondria is 14 μm, while average length of the depicted SCA7 mitochondria is 5 μm. Scale bar, 5 μm\
(F) Quantification of average mitochondrial content by measuring Tom20 immunofluorescence signal as a percentage of calbindin immunofluorescence. Data are represented as mean ± SEM, and each dot represents the result for an individual Purkinje cell soma; 8.5-week-old WT and SCA7 mice; n = 3 mice/genotype, n = 180--190 cells/genotype; \*\*\*\*p \< 0.0001 (two-tailed t test).\
(G) Quantification of average length of the mitochondrial network. Data are represented as mean ± SEM, and each dot represents the results for an individual Purkinje cell soma; 8.5-week-old WT and SCA7 mice; n = 3 mice/genotype, n = 180--190 cells/genotype; \*\*\*\*p \< 0.0001 (two-tailed t test). Error bars indicate SEM.](nihms-1519906-f0003){#F2}

![SCA7 Purkinje Cells Display Abnormal Mitochondrial Morphology\
(A) Representative images of WT Purkinje cell soma and dendrites at 8.5 weeks of age. Red arrowheads indicate mitochondria. Red outlines demarcate the cytosol of a Purkinje cell soma and dendrite to delineate the analyzed area. Bottom: zoom of the yellow boxed region. Scale bars, 1 μm.\
(B) Representative images of SCA7 Purkinje cell soma and dendrites at 8.5 weeks of age. Red arrowheads indicate mitochondria. Red outlines demarcate the cytosol of a Purkinje cell soma and dendrite to delineate the analyzed area. Bottom: zoom of the yellow boxed region. Scale bars, 1 μm.\
(C) Representative graph of the area of individual mitochondria within a single Purkinje cell soma from (A) and (B). Each dot represents an individual mitochondrion;black bars represent the medians.\
(D) Quantification of the medians represented in (C) from the soma and dendrites of analyzed Purkinje cells; 8.5-week-old WT and SCA7 mice; n = 3 mice/genotype, n = 12--19 cells/genotype; \*\*p \< 0.01 and \*\*\*p \< 0.001 (two-tailed t test).\
(E) Representative graph of the perimeter of individual mitochondria within a single Purkinje cell soma from (A) and (B). Each dot represents an individual mitochondrion; black bars represent the medians.\
(F) Quantification of the medians represented in (E) from the soma and dendrites of analyzed Purkinje cells; 8.5-week-old WT and SCA7 mice; n = 3 mice/genotype, n = 12--19 cells/genotype; \*p \< 0.05 and \*\*\*p \< 0.001 (two-tailed t test).\
(G) Representative graph of the feret diameter of individual mitochondria within a single Purkinje cell soma from (A) and (B). Each dot represents an individual mitochondrion; black bars represent the medians.\
(H) Quantification of the medians represented in (G) from the soma and dendrites of analyzed Purkinje cells; 8.5-week-old WT and SCA7 mice; n = 3 mice/genotype, n = 12--19 cells/genotype; \*p \< 0.05 and \*\*\*p \< 0.001 (two-tailed t test). Error bars indicate SEM.](nihms-1519906-f0004){#F3}

![SCA7 Stem Cell Neural Derivatives Exhibit PolyQ Length-Dependent Disease Phenotypes\
(A) Graph of average mitochondrial length of control (10Q) and SCA7 patient (50Q, 65Q, 70Q) neuronal progenitor cells (NPCs) on the basis of Tom20 immunostaining. Quantification of average mitochondrial length analyzed using ImageJ mitochondrial morphometry plugin. Each dot represents the average mitochondrial length from an individual cell, and data are represented as mean ± SEM. Two control patient lines (one or two clones per line) and two SCA7 patient lines (two clones per line); n = 70--100 cells/genotype. \*\*\*p \< 0.001 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(B) Ataxin-7-knockout NPCs were transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. Non-transduced (NT) cells serve as a negative control for transfection. Protein lysates were immunoblotted with anti-ataxin-7 or antiexpanded polyQ tract antibody, as indicated. β-Actin immunoblotting analysis was performed as a loading control.\
(C) Protein lysates from control and SCA7 patient NPCs of the indicated CAG repeat allele size were filtered through nitrocellulose and then immuno-blotted with anti-expanded polyQ tract antibody.\
(D) Protein lysates from non-transduced ataxin-7-knockout NPCs or from ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector were filtered through nitrocellulose and then immunoblotted with anti-expanded polyQ tract antibody.\
(E) Control and SCA7 patient NPCs of the indicated CAG repeat allele size were analyzed for percentage of live cells by fluorescence-activated cell sorting (FACS) for side scatter (SSC-A) and forward scatter (FSC-A). n = 2 clones/genotype except for SCA7 50Q, for which one clone was available; n = 8 replicates/clone. \*\*\*p \< 0.001 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(F) Non-transduced ataxin-7-knockout NPCs or ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector were analyzed for percentage of live cells by FACS for side scatter (SSC-A) and forward scatter (FSC-A). Isogenic lines, one clone per genotype, n = 3 technical replicates. \*p \< 0.05, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 (ordinary one-way ANOVA with post hoc Tukey's multiple-comparison test). Error bars indicate SEM.](nihms-1519906-f0005){#F4}

![SCA7 Stem Cell Neural Derivatives Display PolyQ Length-Dependent Mitochondrial Morphology and Metabolic Defects\
(A) Representative images of Tom20 immunostaining for ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. Scale bar, 5 μm.\
(B) Quantification of average mitochondrial length on the basis of Tom20 immunostaining and ImageJ mitochondrial morphometry analysis. Each dot represents an individual cell, data are represented as mean ± SEM. Isogenic lines, one clone per genotype, n = 34--57 cells/genotype. \*p \< 0.05 and \*\*\*p \< 0.001 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(C) Extracellular flux analysis to measure oxygen consumption rate (OCR) as a function of extracellular acidification rate (ECAR) for non-transduced ataxin-7-knockout NPCs or ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector.\
Oligomycin, FCCP, or antimycin/rotenone (A/R) treatments were given at the indicated time points. Data are represented as mean ± SEM. Isogenic lines, one clone per genotype, n = 5 wells/genotype. Two-way ANOVA with post hoc Dunnett's multiple-comparison test at each time point. Asterisks indicate comparison between ataxin-7-113Q and each other genotype condition (\*\*\*\*p \< 0.0001). Error bars indicate SEM.](nihms-1519906-f0006){#F5}

![SCA7 Stem Cell Neural Derivatives Exhibit Altered NAD^+^ Salvage Pathway Enzyme Expression and Reduced NAD^+^ Levels in the Nucleus and Mitochondria\
(A) qRT-PCR analysis of NMNAT1 gene expression for ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. Isogenic lines, one clone per genotype, n = 3/genotype. \*p \< 0.05 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(B) qRT-PCR analysis of NMNAT2 gene expression for ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. One clone per genotype (all on isogenic background), n = 3/genotype. \*p \< 0.05 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(C) qRT-PCR analysis of NMNAT3 gene expression for ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. One clone per genotype (all on isogenic background), n = 3/genotype. \*\*\*p \< 0.001 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(D) NMNAT1 immunoblot analysis of protein lysates from ataxin-7-knockout NPCs transduced with empty vector, ataxin-7-10Q, or ataxin-7-113Q lentivirus vector. β-Actin immunoblot served as a loading control. Bottom: quantification of NMNAT1 protein expression normalized to β-actin. \*\*p \< 0.01 (one-way ANOVA with post hoc Tukey's multiple-comparison test).\
(E) SCA7 patient NPCs or control NPCs were transfected with a nicotinamide adenine dinucleotide (NAD^+^) biosensor linked to a nuclear localization signal (top), cytosolic localization signal (middle), or mitochondrial localization signal (bottom). After excitation at 488 nm to monitor NAD^+^ binding, which reduces fluorescence, and excitation at 405 nm, which elicits fluorescence in the absence of NAD^+^ binding to normalize sensor expression level, we calculated the emission ratio for SCA7 patient NPCs and control NPCs. An increased fluorescence ratio for SCA7 patient NPCs indicated a reduced level of NAD^+^. NPC lines, two clones per genotype, n = 2/genotype; n = 3 technical replicates. \*p \< 0.05 (unpaired t test). Error bars indicate SEM.](nihms-1519906-f0007){#F6}

![Metabolomics Analysis Reveals Altered Tryptophan Metabolism in SCA7 Patients\
(A--F) We performed high-resolution mass spectrometry in combination with liquid chromatography (LC-HRMS) on plasma samples from 13 fasted SCA7 patients and 35 fasted controls. Depicted are boxplot representations for analyte signal areas in log-~10~, corresponding to (A) tryptophan, (B) kynurenine, (C) kynurenine/tryptophan ratio, (D) 5-hydroxytryptophan, (E) kynurenic acid, and (F) xanthurenic acid. \*\*p \< 0.01 and \*\*\*p \< 0.001 (two-tailed t test). Error bars indicate SEM.](nihms-1519906-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                   SOURCE                          IDENTIFIER
  --------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------
  Antibodies                                                                                            
                                                                                                        
  Mouse anti-Calbindin                                                  Sigma-Aldrich                   Cat\# C9848; RRID:AB_476894
  Rabbit anti-Tom20                                                     Santa Cruz                      Cat\# sc-11415; RRID:AB_2207533
  Anti-mouse superclonal AlexaFluor 488                                 Fisher                          Cat\# A28175; RRID:AB_2536161
  Anti-rabbit AlexaFluor 555                                            Fisher                          Cat\# A-21428; RRID:AB_2535849
  Anti-rabbit AlexaFluor 647                                            Fisher                          Cat\# A27040; RRID:AB_2536101
  Rabbit anti-ATXN7                                                     Thermo                          Cat\# PA1-749; RRID:AB_2061308
  Mouse anti-polyQ 1C2                                                  Millipore                       Cat\# MAB1574; RRID:AB_94263
  Rabbit anti-TOMM20                                                    Novus                           Cat\# NBP1-81556; RRID:AB_11003249
  Mouse anti-MFN1                                                       Abcam                           Cat\# ab57602; RRID:AB_2142624
  Mouse anti-DRP1                                                       Abcam                           Cat\# ab56788; RRID:AB_941306
  Mouse anti-beta actin                                                 Abcam                           Cat\# ab8226; RRID:AB_306371
  Anti-mouse HRP secondary antibody                                     Santa Cruz                      Cat\# sc-2005; RRID:AB_631736
  Anti-rabbit HRP secondary antibody                                    Santa Cruz                      Cat\# sc-2004; RRID:AB_631746
  Chicken anti-GFP                                                      Abcam                           Cat\# ab13970; RRID:AB_300798
  Mouse anti-SSEA4                                                      Cell Signaling                  Cat\# 4755; RRID:AB_1264259
  Mouse anti Tra-1-60                                                   Cell Signaling                  Cat\# 4746; RRID:AB_2119059
  Mouse anti Tra-1-81                                                   Cell Signaling                  Cat\# 4745; RRID:AB_2119060
  Rabbit anti-Pax6                                                      Covance                         Cat\# PRB-278P; RRID:AB_291612
  Mouse anti-Nestin                                                     Abcam                           Cat\# ab6142; RRID:AB_305313
                                                                                                        
  Bacterial and Virus Strains                                                                           
                                                                                                        
  DH5-a                                                                 Life Technologies               18265017
                                                                                                        
  Biological Samples                                                                                    
                                                                                                        
  Patient and control primary fibroblasts                               This paper                      N/A
                                                                                                        
  Chemicals, Peptides, and Recombinant Proteins                                                         
                                                                                                        
  mTesR1 medium                                                         Stem Cell Technologies          Cat. 85850
  Matrigel                                                              BD Biosciences                  356234
  Prolong Gold anti-fade reagent                                        ThermoFisher                    P36930
  cOmplete ULTRA mini protease inhibitor                                Roche                           5892791001
  GE Healthcare Amersham ECL Prime Western Blotting Detection Reagent   Denville Scientific             E3018
  ROCK inhibitor (Ri) Y-27632 dihydrochloride                           Tocris                          125410
  Accutase                                                              ThermoFisher                    A1110501
  STEMdiff Neural Induction Medium                                      StemCell Technologies           05835
  STEMdiff Neural Progenitor Medium                                     StemCell Technologies           05833
  FK866 chemical                                                        Life Technologies               XP00165BOX
  Hoechst 33342                                                         Life Technologies               H3570
                                                                                                        
  Critical Commercial Assays                                                                            
                                                                                                        
  TURBO DNA-free kit                                                    ThermoFisher                    AM1907
  High-Capacity cDNA Reverse Transcription Kit                          ThermoFisher                    4368814
  TaqMan Universal Master Mix II                                        Life Technologies               4440040
  BCA assay                                                             Pierce; ThermoFisher            23225
  Surveyor Nuclease Kit                                                 Transgenomic                    706025
  Amaxa Human Stem Cell Nucleofector Kit 2                              Lonza                           VPH-5022
  DNeasy Blood and Tissue Kit                                           QIAGEN                          69504
  PCRx enhancer system                                                  Invitrogen, Life Technologies   11495017
  TOPO-TA cloning kit                                                   ThermoFIsher                    451641
  QIAprep Spin Miniprep Kit                                             QIAGEN                          27106
  Seahorse XF Cell Mito Stress Test Kit                                 Agilent                         103015-100
                                                                                                        
  Experimental Models: Cell Lines                                                                       
                                                                                                        
  HeLa cells                                                            N/A                             N/A
                                                                                                        
  Experimental Models: Organisms/Strains                                                                
                                                                                                        
  SCA7 266Q mice                                                        H. Zoghbi                       [@R64]
                                                                                                        
  Oligonucleotides                                                                                      
                                                                                                        
  NMNAT1 Taqman probe                                                   Life Technologies               Hs00978912_m1
  *ATXN7* gRNA (CGGGCCGCGGATGACGTCAGG)                                  Life Technologies               Customized GeneArt DNA string
  SCA73.1F 5′-GAGCGGAAAGAATGTCGGAGCG-3′                                 IDT                             N/A
  SCA73.327R 5′-CAGGAACTTTGGAAGCCTCAACCC-3′                             IDT                             N/A
                                                                                                        
  Recombinant DNA                                                                                       
                                                                                                        
  Oct4, Sox2, Klf4, c-Myc plasmids (Yamanaka factors)                   A. Muotri                       [@R4]
  pUC57 N/A                                                             A. Muotri                       [@R54]
  CMV::Cas9-2A-eGFP                                                     Addgene                         RRID:Addgene_44719
  CMV::Cas9D10A-2A-EGFP                                                                                 RRID:Addgene_44720
  EGFP-2A-puroR-2A                                                      This paper                      N/A
  EGFP-2A-puroR-2A-Atxn7cDNA (10 CAG)                                   This paper                      N/A
  EGFP-2A-puroR-2A-Atxn7cDNA (113 CAG)                                  This paper                      N/A
  Cytoplasmic NAD sensor                                                L. Cambronne                    [@R3]
  Nuclear NAD sensor                                                    L. Cambronne                    [@R3]
  Mitochondrial NAD sensor                                              L. Cambronne                    [@R3]
  Cytoplasmic cpVenus control                                           L. Cambronne                    [@R3]
  Nuclear cpVenus control                                               L. Cambronne                    [@R3]
  Mitochondrial cpVenus control                                         L. Cambronne                    [@R3]
                                                                                                        
  Software and Algorithms                                                                               
                                                                                                        
  MitoDB database                                                       [@R48]                          [www.mitodb.com](http://www.mitodb.com/)
  GraphPad Prism                                                        GraphPad Software               N/A
  ImageJ                                                                N/A                             <https://imagej.nij.com/ij/>
  ImageJ mitochondrial morphometry plugin                               [@R8]                           From author
  cnvPartition progra                                                   Illumina                        N/A
  gada R package                                                                                        <http://www.creal.cat/jrgonzalez/software.htm#ancla-MAD>
  E-CRISP design site                                                   [@R23]                          <http://www.e-crisp.org/E-CRISP/>
  SigmaPlot                                                             Systat Software                 <https://systatsoftware.com/>
  Origin                                                                Origin Labs                     <https://www.originlab.com/>
  galaxy workflow4metabolomics                                          [@R16]                          <https://galaxy.workflow4metabolomics.org/>

###### Highlights

-   SCA7 patients display impaired oxidative metabolism on magnetic resonance spectroscopy

-   Oxygen consumption and respiration are markedly decreased in SCA7 model mice

-   Mitochondrial fragmentation occurs in SCA7 mouse Purkinje cells and iPSC-derived neurons

-   NAD^+^ is markedly reduced in nucleus and mitochondria of SCA7 patient-derived neurons
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